Drag a card by its title · ⚙ to size, swap or remove

The company

Spyre Therapeutics, Inc.

SYRE · Nasdaq

Health CareBiotechnologyJust dropped out

SYRE stood above a rising 150-day average in 51 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 1.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Just dropped out
Weeks in an uptrend: out for 1
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $878.2M
Officials’ trades on record: 0
Institutions holding: 252 (+62)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 51 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0

Sale orders, 12 months34

Buyers · sellers0 · 7

Who	Did	Shares	Traded
Scott L. BurrowsChief Financial Officer	sold	600at $89.07	1 Oct 2026filed 2 Oct 2026
Scott L. BurrowsChief Financial Officer	sold	1,500at $90.27	1 Oct 2026filed 2 Oct 2026
Scott L. BurrowsChief Financial Officer	sold	2,100at $91.92	1 Oct 2026filed 2 Oct 2026
Scott L. BurrowsChief Financial Officer	sold	3,071at $92.95	1 Oct 2026filed 2 Oct 2026
Scott L. BurrowsChief Financial Officer	sold	229at $93.57	1 Oct 2026filed 2 Oct 2026
Cameron TurtleChief Executive Officer	sold	600at $89.14	1 Oct 2026filed 2 Oct 2026
Cameron TurtleChief Executive Officer	sold	2,683at $90.10	1 Oct 2026filed 2 Oct 2026
Cameron TurtleChief Executive Officer	sold	2,638at $91.49	1 Oct 2026filed 2 Oct 2026
Cameron TurtleChief Executive Officer	sold	3,989at $92.31	1 Oct 2026filed 2 Oct 2026
Cameron TurtleChief Executive Officer	sold	4,990at $93.37	1 Oct 2026filed 2 Oct 2026
Cameron TurtleChief Executive Officer	sold	100at $93.91	1 Oct 2026filed 2 Oct 2026
Heidy King-JonesOfficer	sold	400at $89.24	1 Oct 2026filed 2 Oct 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders252+62 on the quarter

New · exited88 · 23

Reported value$8.3B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
FMR LLCadded · filed 13 Aug 2026	13,026,187$1.2B	+1,245,163+10.6%
BlackRock, Inc.added · filed 7 Aug 2026	6,506,605$577.7M	+985,384+17.8%
PERCEPTIVE ADVISORS LLCadded · filed 14 Aug 2026	4,319,496$383.5M	+536,271+14.2%
RTW INVESTMENTS, LPadded · filed 14 Aug 2026	4,251,996$377.5M	+80,000+1.9%
Paradigm Biocapital Advisors LPadded · filed 14 Aug 2026	3,840,778$341.0M	+1,883,512+96.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	3,448,681$306.2M	+391,280+12.8%
STATE STREET CORPadded · filed 7 Aug 2026	3,057,416$271.4M	+450,385+17.3%
Venrock Adviser, LLCreduced · filed 14 Aug 2026	2,985,448$265.0M	-700,000−19.0%
Driehaus Capital Management LLCadded · filed 14 Aug 2026	2,799,166$248.5M	+8,381+0.3%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	2,562,265$239.3M	+841,353+48.9%